HXXB.F · Idera Pharmaceuticals, Inc

-

Please sign in to comment on HXXB.F

1 Comment

Admin

4 years, 1 month ago

Idera Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 61.8% below its 200 day moving average.

From a valuation standpoint, the stock is 96.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 42.2.

Idera Pharmaceuticals, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.

Its net income has dropped by 230.2% to $-77M since the same quarter in the previous year.

Finally, its free cash flow grew by 26.6% to $-8M since the same quarter in the previous year.

Based on the above factors, Idera Pharmaceuticals, Inc gets an overall score of 2/5.

ISIN	US45168K4058
Sector	Healthcare
Industry	Biotechnology
Exchange	F
CurrencyCode	EUR

Market Cap	22M
PE Ratio	None
Target Price	1
Beta	1.3
Dividend Yield	0.0%

ABOUT

Idera Pharmaceuticals, Inc

Idera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, squamous cell carcinoma of the head and neck, and colorectal cancer. The company has a collaboration agreement with Bristol-Meyers Squibb. Idera Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.

HXXB.F · Idera Pharmaceuticals, Inc

-

Idera Pharmaceuticals, Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Idera Pharmaceuticals, Inc using a moving average strategy